ImmunityBio (IBRX) versus Its Rivals Critical Analysis

ImmunityBio (NASDAQ:IBRX) is one of 283 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its competitors? We will compare ImmunityBio to related businesses based on the strength of its profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Valuation and Earnings

This table compares ImmunityBio and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ImmunityBio	$620,000.00	-$583.20 million	-4.24
ImmunityBio Competitors	$562.03 million	-$37.01 million	6.75

ImmunityBio’s competitors have higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

ImmunityBio has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, ImmunityBio’s competitors have a beta of 1.05, indicating that their average stock price is 5% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for ImmunityBio and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	0	1	0	0	2.00
ImmunityBio Competitors	1411	4450	11710	206	2.60

ImmunityBio currently has a consensus price target of $5.00, indicating a potential upside of 1.63%. As a group, “Biological products, except diagnostic” companies have a potential upside of 119.39%. Given ImmunityBio’s competitors stronger consensus rating and higher probable upside, analysts clearly believe ImmunityBio has less favorable growth aspects than its competitors.

Institutional and Insider Ownership

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 50.7% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 83.4% of ImmunityBio shares are owned by insiders. Comparatively, 16.1% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares ImmunityBio and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-93,761.41%	N/A	-114.56%
ImmunityBio Competitors	-4,534.25%	-228.18%	-45.56%

Summary

ImmunityBio competitors beat ImmunityBio on 10 of the 13 factors compared.

About ImmunityBio

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies. Its lead biologic commercial product candidate is Anktiva, an IL-15 superagonist antibody-cytokine fusion protein for the treatment of bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease. The company also develops other therapeutic agents for the treatment of liquid and solid tumors, including bladder, lung, colorectal, and ovarian cancers, as well as glioblastoma multiforme, acute myeloid leukemia, and human immunodeficiency virus. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., and Viracta Therapeutics, Inc. The company is based in San Diego, California.